The Federal Trade Commission (FTC) is scrutinizing mergers more carefully than in the past. The federal agency is currently trying to block a merger between Amgen and Horizon Therapeutics.
In its lawsuit, the FTC said that if it allowed Amgen’s $27.8 billion purchase to go through, Amgen could pressure the companies that manage access to prescription drugs — pharmacy benefit managers, or PBMs — to boost the two extremely expensive Horizon products in a way that would inhibit any competition.
In was the dawn of the 21st Century when untreated pain became a public health priority. In 1990 Dr. Mitchel Max, then president of the American Pain Society, authored an editorial in the Annals of Internal Medicine lamenting the lack of progress treating pain over the previous two decades. Within a few years Joint Commission jumped on the bandwagon and published Pain: The Fifth Vital Sign. Thus began America’s experiment in aggressive pain treatment and its descent into opioid addiction and overdose deaths.